7, 8-dihydroxyflavone ameliorates cholinergic dysfunction, inflammation, oxidative stress, and apoptosis via activation of Akt/CREB/BDNF signaling pathway in a rat model of vascular dementia

doi:10.21203/rs.3.rs-3239088/v1

Download PDF

Research Article

7, 8-dihydroxyflavone ameliorates cholinergic dysfunction, inflammation, oxidative stress, and apoptosis via activation of Akt/CREB/BDNF signaling pathway in a rat model of vascular dementia

https://doi.org/10.21203/rs.3.rs-3239088/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 01 Feb, 2024

Read the published version in Neurochemical Research →

You are reading this latest preprint version

Background

Vascular dementia (VD) is a degenerative cerebrovascular disorder associated with progressive cognitive decline. Previous reports have shown that 7,8-dihydroxyflavone (7,8-DHF), a well-known TrkB agonist, is effective in ameliorating cognitive deficits in several disease models. Therefore, this study investigated the protective effects of 7,8-DHF against 2-VO-induced VD.

Methods

VD was established in rats using the permanent bilateral carotid arteries occlusion (two-vessel occlusion, 2-VO) model. 7,8-DHF (5, 10, and 20 mg/kg) and Donepezil (10 mg/kg) were administered for 4 weeks. Memory function was assessed by the novel objective recognition task (NOR) and Morris water maze (MWM)tests. Inflammatory (TNF-α, IL-1β, and NF-kβ), oxidative stress, and apoptotic (Bax, Bcl-2, caspase-3) markers, along with the activity of choline acetylcholinesterase (AChE) was assessed. p-AKT, p-CREB, BDNF, and neurotransmitter (NT) (GLU, GABA, and ACh) levels were also analyzed in the hippocampus of 2-VO rats.

Results

Our results show that 7,8-DHF effectively improved memory performance, and cholinergic dysfunction in 2-VO model rats. Furthermore, 7,8-DHF treatment also increased p-AKT, p-CREB, and BDNF levels, suppressed oxidative, inflammatory, and apoptotic markers, and restored altered NT levels in the hippocampus.

Conclusions

These findings imply that 7, 8-DHF may act via multiple mechanisms and as such serve as a promising neuroprotective agent in the context of VD.

2- VO

Cognitive decline

vascular dementia

8-DHF

BDNF

Glutamate

Vascular dementia (VD) is a progressive neurodegenerative disease that is known to account for 20% of all cases of dementia [1]. In older adults, it is second most prevalent type of dementia after AD [2]. VD is known to be associated with impairment of executive functions such as working memory, planning, thinking, reasoning, problem-solving, judgment, and the execution of tasks [3]. Advanced age, smoking, hypertension, diabetes, generalized atherosclerosis, and atrial fibrillation are important risk factors for VD [4]. Chronic cerebral hypoperfusion (CCH) represents an important cause of VD. Neuronal energy failure secondary to reduced blood flow may promote the production of reactive oxygen species, initiating neuronal apoptosis and ultimately leading to functional deficits associated with VD [5]. Presently, no specific treatments are available highlighting the need for developing new effective treatment strategies for tackling VD.

Brain-derived neurotrophic factor (BDNF) is one of the most widely studied growth factors known to promote neuronal survival and differentiation [6]. BDNF is known to regulate synaptic transmission and hippocampal neuroplasticity which is crucial for cognitive function [7]. It is known to promote neuronal survival and prevent apoptosis by activating various signalling pathways such as phospholipase C-γ, PI3K, and MAPK through its receptor tropomyosin-related kinase B (TrkB). Furthermore, previous studies have reported CCH inhibits BDNF signalling whereas its enhancement may prevent CCH-induced hippocampus neuronal damage and cognitive impairment[8, 9]. In clinical trials, recombinant BDNF has yielded disappointing results. As a result, various small-molecule ligands that can stimulate the TrkB receptor are being pursued as alternative agents for treating neurological diseases.

7,8-Dihydroxyflavone (7,8-DHF), a flavone derivative, is a potent and selective TrkB agonist known to penetrate the brain-blood barrier [10]. 7,8-DHF is known to mimic the physiological actions of BDNF by binding to the extracellular domain of the TrkB receptor [11]. As a result, 7,8-DHF has demonstrated its therapeutic efficacy in several animal disease models linked to deficient BDNF signalling [12]. It has shown anti-apoptotic, anti-oxidant, anti-inflammatory, anti-depressant, and neuroprotective activity along with efficacy in neurodegenerative diseases, traumatic brain injury, and glutamate-induced neurotoxicity [13]. Moreover, treatment with 7,8-DHF has also been proven to reverse cognitive deficits in various disease models via multiple mechanisms [14–16]. However, to date, no study has reported the role of 7,8-DHF in VD. Therefore, the present study was undertaken to investigate the therapeutic effects of 7,8-DHF on learning and memory function in a rat model of VD.

2.1 Animals

Male Sprague-Dawley rats (200–250 gm) bred at the central animal house, Panjab University, Chandigarh were used. Animals were kept under standard laboratory conditions (25 ± 2°C, 60–70% humidity, and 12-h light and dark cycle). Standard rodent food pellets and water were available ad libitum throughout the study. All experiments were performed in agreement with the guidelines of the committee for the purpose of control and supervision of experiments on animals (CPCSEA). The experimental protocols were approved by the Institutional Animal Ethical Committee (PU/45/99/CPCSEA/IAEC/2018/78).

2.2 Drugs and reagents

7,8-DHF and donepezil (DNPZ) were purchased from TCI Chemicals, India. NF-kβ, Bax, Bcl-2 (Elabscience, Wuhan, China), TNF-α, IL-1β (PeproTech, Rocky Hill, NJ, USA), p-AKT, p-CREB (Bioassay Technology Laboratory, China) and BDNF (Merck Millipore, Billerica, MA, USA) levels were measured using ELISA kits. Furthermore, Caspase-3 activity was estimated using a commercially available colorimetric assay kit (BioVision, Inc., Milpitas, CA, USA).

2.3 Surgical procedure and drug treatment

Rats were anesthetized with ketamine (80 mg/kg) and xylazine (5 mg/kg). A midline cervical incision was made and the bilateral carotid arteries were carefully separated from the vagus nerve and carotid sheath. Thereafter, each carotid artery was ligated with a 5–0 silk suture. In sham-operated rats, an identical surgical procedure was carried out, but without carotid artery ligation. A heating lamp was used during the surgery to prevent hypothermia [17]. After surgery, all rats were randomly divided into six different groups (n = 8–10) as follows: a sham group, a sham + 7,8-DHF (20 mg/kg) group, a 2-VO group, a DNPZ (10 mg/kg) group and 7,8-DHF (5,10 and 20 mg/kg) groups. 7,8-DHF (5,10 and 20 mg/kg) was prepared in phosphate-buffered saline (PBS) containing 17% DMSO and administered through the intraperitoneal (i.p.) route. DNPZ (10mg/kg) was dissolved in 0.5% CMC-Na and administered orally. Both drugs were daily administered for 4 weeks. Doses for DNPZ and 7,8-DHF were selected based on earlier studies [18, 19].

2.4 Behavioral assessments

2.4.1 Closed field activity

Closed field activity was performed on day 29. The apparatus consisted of a squared closed arena (30 × 24 × 22 cm³) which was equipped with 16 infrared light-sensitive photocells that were present in two rows. During the habituation phase, each animal was kept for at least 2–3 min in the chamber. Thereafter, locomotor activity was measured for 5-min during which rearing and ambulatory scores of each rat were recorded [18].

2.4.2 Morris water maze test

The MWM test was performed from day 30 to 34 [20]. The test was conducted in a black circular tank (diameter,180 cm; depth, 60 cm) that was filled to a depth of 40 cm with water (28.5 ± 2^°C). At the center of one of the quadrants, a hidden platform (diameter, 12.5; height 38 cm) was placed 2 cm below the surface of the water. Several prominent cues whose position remained unchanged throughout the experiment were placed external to the pool. The rats were given training for 4 consecutive days. During each training trial, the time taken for the rat to reach the platform (latency period) was noted. Rats that failed to find the platform within 90 s cut-off period time were guided to the platform and were allowed to sit on the platform for 20 s. A probe trial was conducted on day 5, during which no platform was present. The time spent and the number of entries into the target quadrant was recorded.

2.4.3 Novel object recognition (NOR) test

The NOR test was performed as described previously [17]. Briefly, on day one, during the habituation phase animals were familiarized for some time of 5 min by placing them in a circular open field arena (50 cm in diameter and height 40 cm) without any objects. During the training phase, two identical objects were placed in the arena and rats were allowed to investigate them for 5 min. Twenty-four hours after the training phase, one familiar object was substituted by a novel object, and the exploration time was recorded. The discrimination index was calculated using the formula: (T_N – T_F)/(T_{N +} T_F) where T_F: Time spent exploring the familiar object; T_N: Time spent exploring the novel object.

2.4.4 Tissue sampling

After the behavioural tests, rats were sacrificed for cervical dislocation and the brains of rats were taken out carefully. The hippocampus was dissected quickly and homogenized in 10% (w/v) of 0.1M of PBS. Homogenates obtained were centrifuged at 10000×g for 20 minutes at 4^°C. For the BDNF assay, hippocampus tissues were homogenized in an ice-cold buffer (100 mM Tris/HCl containing 1M NaCl, 0.1% sodium azide, 2% bovine serum albumin (BSA), 2% Triton X-100, 4 mM EDTA, and protease inhibitors).

2.4.5 Estimation of lipid peroxidation

The extent of lipid peroxidation (LPO) in the hippocampus was measured by the method of [21]. Briefly, a reaction mixture involving Tris-HCL and supernatant (0.5ml) was incubated for 2 h at 37^°C. Thereafter, 1 ml of 10% TCA (10% w/v) was added to the incubated mixture and this was followed by centrifugation for 10 min at 1000×g. To the supernatant obtained 1 ml of thiobarbituric acid (0.67% w/v) was added and this mixture was kept in boiling water for 10 min. On cooling, distilled water (1 ml) was added to the samples. Absorbance was measured at 532 nm and results were expressed as a nanomole of malondialdehyde per milligram protein.

2.4.6 Estimation of protein carbonyls

Protein carbonyl levels were measured by incubating 20 mM of 2, 4-dinitrophenylhydrazine (DNPH) solution and 100 µl of homogenate for 1 h. Thereafter, 120 µl of 20% (w/v) TCA was added and centrifuged at 10,000×g for 10 min after keeping it on ice for 10 min. An ethyl acetate-ethanol–mixture (1:1) was used to wash the pellets obtained which were subsequently dissolved in 6 M guanidine–HCl solution (1 ml). Absorbance was determined spectrophotometrically at 370 nm and the protein carbonyl content was expressed as nmol/mg protein[22].

2.4.7 Estimation of reduced glutathione levels (GSH)

For estimating reduced glutathione levels,1 ml of sulphosalicylic acid(4%w/v) was added to tissue homogenate which was kept at 4^°C for 1 h and centrifuged for 15 min at 1200 ×g. Thereafter, 0.2 ml of 0.01 M DTNB and 2.7 ml of phosphate buffer (0.1M, pH 8) were added to the supernatant (0.1 ml), and absorbance was measured at 412 nm. GSH levels were expressed as µM per mg protein[23].

2.4.8 Estimation of superoxide dismutase activity

SOD activity was determined by adding homogenate (0.05 ml) to an assay mixture consisting of 50 mM sodium carbonate, 0.05 ml hydroxylamine hydrochloride (pH 6.0), 0.1 mM ethylenediaminetetraacetic acid (EDTA), and 96 mM of nitro blue tetrazolium (NBT). Thereafter, a change in absorbance was observed at 560nm for 2 min at 30/60s intervals and SOD activity was expressed as units per milligram protein[24].

2.4.9 Estimation of catalase activity

The activity of catalase was determined according to a previously described method [18]. Briefly, to an assay mixture consisting of 1.0 ml hydrogen peroxide (0.019 M) and 1.95 ml phosphate buffer (0.05 M, pH 7.0), 0.05 ml homogenate was added. The change in absorbance was measured at 240 nm. Catalase activity was expressed as µM of H₂O₂ decomposed per minute per milligram protein.

2.4.10 Estimation of glutathione peroxidase (GSH-Px) activity

GSH-Px was estimated by a previously described method [25]. Briefly, to the sample (0.1 ml), 10 µl of 0.25 mM hydrogen peroxide, 100 µl of 1 mM sodium azide, 1.44 ml of 50 mM potassium phosphate buffer (pH 7.0), 100 µl of 0.2 mM NADPH, 50 mm potassium phosphate buffer, 100µl of 1 mM EDTA, and 50 µl of glutathione reductase was added. Absorbance was measured spectrophotometrically at 340 nm at 37^°C for 2 min at each 60 sand GSH-Px activity was expressed as nmol/min/mg protein.

2.4.11 Estimation of acetylcholinesterase (AChE) activity

A reaction mixture consisting of 50 µl of tissue homogenate, 3 ml of 0.01 M sodium phosphate buffer (pH 8.0), 100 µl of acetylthiocholine iodide, and 100µl5,5, dithiobis-(2-nitro benzoic acid) was taken. AChE activity was measured using molar extinction co-efficient 1.36×10⁴ M^− 1 cm^− 1 at 412 nm and measured as nmol of acetylthiocholine iodide hydrolyzed/min/mg protein[26].

2.4.12 Neurotransmitter analysis

Glutamate (Glu), acetylcholine (ACh), and γ-aminobutyric acid (GABA), levels were measured in the hippocampus of 2-VO rats. For Glu estimation, the hippocampus was homogenized in perchloric acid and centrifuged for 10 min at 3000 ×g. An assay system consisting of 10 µl of 33.5 m M ADP, 20 µl of 27 mM NAD, and 200 µl of glycine-hydrazine buffer was taken to which 100µl of tissue homogenate was added. Extinction E₁ was read at 340 nm. Thereafter, 5 µl of glutamate dehydrogenase (GlDH) was added and extinction E_{2 was} measured. The difference between E1 and E₂ was calculated for sample and blank and ∆ E _{s a m} - E_{b l k} = ∆ E _{g l u} was subsequently used for the calculations. Glu content in the hippocampus was expressed as µmol/g [27]. Regarding the ACh assay, a reaction mixture consisting of 0.2 ml of supernatant, 0.25 ml of 2 M calabarine sulfate, 0.2 ml of 1.85 M TCA, and 0.375 ml of pure water was incubated at room temperature and subsequently centrifuged for 10 min at 2000×g. The supernatant obtained was mixed with 2 M hydroxylamine for 10 min. An equal amount (0.125 ml) of 0.37 M ferric chloride and 4 M HCl was added to stop the reaction. Absorbance was measured at 540 nm and ACh was expressed as µM per mg protein. GABA levels were measured as previously described [28]. Briefly, hippocampus tissues were homogenized in 0.01M HCl. Thereafter, 0.2 ml of 0.14 M ninhydrin solution prepared in 0.5 M carbonate bicarbonate buffer was added to 0.1 ml of tissue homogenate. The solution was heated (60°C) for 30 min and cooled. Thereafter, 5 ml of copper tartrate reagent (0.0329% tartaric acid, 0.16% sodium carbonate, 0.03% copper sulfate) was added. After 10 min fluorescence emission was noted at 377/455 nm.

2.5 Enzyme-Linked Immunosorbent Assay (ELISA)

2.5.1 TNF-α and IL-1β estimations

The level of TNF-α and IL-1βwere measured according to the manufacturer’s instructions. Briefly, 100 µl of Capture Antibody (anti-TNF-α and anti-IL-1β) was used to coat the ELISA plates overnight. Thereafter, plates were repeatedly washed and tissue homogenate (100 µl)was added and incubated for 2 h. To each well Avidin-HRP Conjugate (100µl) was added after washing followed by incubation for 30 minutes at room temperature. The washing step was subsequently repeated and 100 µl of Avidin-horseradish peroxidase conjugate was added. Finally, after washing each well ABTS Liquid Substrate was added and the color development was measured at 405nm.

2.5.2 p-AKT and p-CREB estimations

To estimate p-AKT and p-CREB levels hippocampus homogenate (100 µl) was added to pre-coated antibody-specific wells for p-AKT and p-CREB for 60 min at 37°C. The plate was washed subsequently. Thereafter, 50 µl of substrate solutions were added and incubated for 10 minutes at 37°Cin the dark. Finally, to each well 50µl of stop solution was added and the plate was read using a microplate reader set to 450 nm.

2.5.3 BDNF Estimation

The hippocampus tissues were homogenized in an ice-cold buffer (1M NaCl, 100 mM Tris/HCl (pH 7), 2% Triton X-100, 2% bovine serum albumin (BSA), 4 mM EDTA, 0.1% sodium azide, and protease inhibitors) followed by centrifugation at 14,000×g for 30 minutes (Eppendorf, model 5430R). The tissue homogenate (100µl) was added to each well and incubated at a 2–8° overnight. This was followed by repetitive washing and the addition of biotinylated detection antibody and incubation for 2–3 hours. Thereafter, streptavidin-HRP conjugate solution was added and this was followed by the addition of 100 µl 3,3′,5,5′-Tetramethylbenzidine (TMB) after an hour. A stop solution was added and absorbance was recorded at 450 nm.

2.5.4 NF-kβ, Bcl-2, and Bax estimations

To assess Bcl-2, Bax, and NF-kβ levels tissue homogenate (100 µl) was added to an ELISA plate, pre-coated with monoclonal antibodies specific for Bcl-2, Bax, and NF-kβ for 90 min. Thereafter, a biotinylated detection antibody was added followed by incubation for 1 hour at 37˚C. The plate was repetitively washed followed by the addition of HRP Conjugate for 30 min. The washing step was subsequently repeated and the substrate reagent was added and incubated for 15–30 min Finally, stop solution (50 µL) was added to each well. The absorbance of samples was read at 450 nm using a microplate reader (Bio-Rad Model 550; CA, USA).

2.6 Statistical analysis

All experimental data were analysed using Graph Pad Prism 6.0 software (Graph Pad, San Diego, USA) and results were presented as mean ± SEM. The escape latency data in the MMW was assessed using the two-way repeated-measures analysis of variance (ANOVA) followed by the Bonferroni multiple comparison post hoc test. For the rest of the data, a statistical comparison was made by one-way ANOVA followed by Tukey’s post hoc test. Results were considered to be statistically significant if p < 0.05 was considered.

3.1 Effect of 7, 8 DHF on locomotor activity in 2-VO rats

Regarding locomotor activity, no statistically significant difference was observed among various groups during the study (p = 0.7734, Fig. 3).

3.2 Effect of 7, 8 DHF on cognitive function in 2-VO rats

In MWM, the escape latency is measured as the time taken to reach a hidden platform and in repeated trials, a decrease in retention latency time indicates intact learning and memory function [29]. As shown in Fig. 4a, significantly longer escape latency was observed in 2-VO rats from day 3onwards when compared to the sham group. A two-way repeated measure ANOVA analysis detected a significant effect of both treatment [F (6, 35) = 5.879, p < 0.001) and time [F (4, 140) = 110.3, p < 0.001] while the interaction between these factors was not significant [F (24, 140) = 1.068, p = 0.3882]. Furthermore, we found that on days 4 and 5, 7,8-DHF (20 mg/kg) treatment significantly decreased escape latencies (p < 0.05). 7, 8-DHF (10 mg/kg) and DNPZ group had a shorter escape latency on day 5 (p < 0.05). In addition, fewer crossings [F (6, 35) = 8.318, p < 0.001] and lesser time F (6, 35) = 7.723, p < 0.001] was spent by the 2-VO rats during the probe trial (Fig. 4b&c). However, both probe trial parameters were significantly improved on treatment with 7, 8-DHF (20 mg/kg), and DNPZ. Furthermore, no significant difference was observed in swimming speeds (p = 0.1093) among the groups (Fig. 4d). In the NOR test, the discrimination index was significantly decreased [F (6, 35) = 4.875, p < 0.01, Fig. 4e] in the 2 -VO group. 7, 8-DHF (10 and 20 mg/kg) and DNPZ treatment attenuated impairment in recognition memory reflected by improvement in discrimination index (p < 0.05).

3.3 Effect of 7, 8 DHF on hippocampal cholinergic activity in 2-VO rats

Disruption in cholinergic signalling has been observed in VD. AChE is an enzyme that is responsible for catalyzing the hydrolysis of ACh into acetate and choline leading to a reduction in the neurotransmitter levels in the brain. As shown in Fig. 5, a significant increase in AChE activity [F (6, 35) = 10.58, p < 0.001] was observed in the hippocampus of 2-VO rats when compared to the sham group. In contrast, the administration of 7,8-DHF (10 and 20 mg/kg) and DNPZ were able to reduce AChE activity.

3.4 Effect of 7, 8 DHF on hippocampal oxidative stress and anti-oxidant status

As shown in Table 1, hippocampal MDA [F (6, 35) = 10.82, p < 0.001] and PCO [F (6, 35) = 8.752, p < 0.001] levels were significantly increased in 2-VO rats. Treatment with 7,8-DHFdose dependently reduced MDA levels. Also, 7, 8-DHF (10 and 20 mg/kg) reduced PCO (p < 0.05, p < 0.01) levels in the hippocampus. Furthermore, the SOD [F (6, 35) = 10.02, p < 0.001], GSH-P_X [F (6, 35) = 9.301, p < 0.001], and CAT [F(6,35) = 7.984, p < 0.01] enzymatic activities along with GSH [F (6, 35) = 10.79, p < 0.001] levels were also reduced in the hippocampus of 2-VO rats. However, treatment with 7,8-DHF (10 and 20 mg/kg) increased CAT and GSH-Px activity and GSH levels. 7,8-DHF (20mg/kg) treatment also enhanced hippocampal SOD activity (p < 0.05).

3.5 Effect of 7, 8-DHF on hippocampal TNF-α, IL-1β, and NF-kβ levels

As shown in Fig. 6a-c, TNF-α [F (6, 14) = 9.752, p < 0.001, Fig. 5a], IL-1β [F (6, 14) = 16.53, p < 0.001, Fig. 5b] and NF-kβ [F (6,14) = 4.562, p < 0.05, Fig. 5c] levels were significantly elevated in the hippocampus of 2-VO rats. Treatment with 7,8-DHF (20 mg/kg) inhibited hippocampal TNF-α (p < 0.05) and NF-kβ (p < 0.05) levels in 2-VO rats. Moreover, treatment with 7,8-DHF dose-dependently attenuated elevated IL-1β levels in the hippocampus of 2-VO rats.

3.6 Effect of 7, 8-DHF on hippocampal p-AKT, p-CREB, and BDNF levels in 2-VO rats

A marked reduction in p-AKT [F (6, 14) = 13.2, p < 0.001, Fig. 7a], p-CREB [F (6, 14) = 9.186, p < 0.001, Fig. 7b], and BDNF [F (6, 14) = 9.893, p < 0.01, Fig. 7c] levels was observed in the hippocampus of 2-VO rats. However, 7,8-DHF (20 mg/kg) treatments significantly increased hippocampal p-AKT, p-CREB, and BDNF levels (p < 0.05). Furthermore, 7,8-DHF (10 mg/kg) also enhanced BDNF levels in the hippocampus although the results were statistically non-significant.

3.7 Effect of 7, 8-DHF on hippocampal Bcl-2, Bax and caspase-3 levels in 2-VO rats

Our results showed that the Bcl-2 [F (6, 14) = 5.938, p < 0.01, Fig. 8a] levels were significantly decreased whereas Bax [F (6, 14) = 8.390, p < 0.001, Fig. 8b] levels were significantly higher in the hippocampus of 2-VO rats. Moreover, hippocampal caspase-3 [F (6, 14) = 4.931, p < 0.05, Fig. 8c) activity was also elevated in 2-VO rats. However, 7,8-DHF (10 and 20 mg/kg) and DNPZ treatments significantly reduced Bax levels and caspase-3 activity (p < 0.05). In contrast, 7, 8-DHF (20 mg/kg) significantly increased hippocampal Bcl-2 (p < 0.05) levels in 2-VO rats.

3.8 Effect of 7, 8 DHF on hippocampal ACh, GABA, and Glu levels in 2-VO rats

A significant increase in GLU [F (6, 14) = 7.169, p < 0.01] levels and reduction in Ach [F (6, 14) = 13.44, p < 0.001] levels was observed in the hippocampus of 2-VO rats when compared to the control group (Table 2). Hippocampal GABA levels were also decreased although the results were not statistically significant (p = 0.3726). Nevertheless, treatment with 7,8-DHF (10 and 20 mg/kg) and DNPZ increased ACh levels compared to vehicle-treated 2-VO rats. Moreover, 7,8-DHF (20 mg/kg) treatment also significantly reduced hippocampal GLU levels (p < 0.05).

VD is caused by a persistent but moderate reduction in cerebral blood flow (CBF) to distinct brain regions causing the deprivation of oxygen and nutrients to the brain and leading to cell death[30]. Over the years, the biochemical mechanisms involved in hypoperfusion-induced cognitive decline have been studied using the 2-VO model. This model is known to exhibit memory or cognitive impairment in various animal behavioural tests along with inflammatory reactions, blood–brain barrier disruption, and neuronal damage in the brain [31]. As such, potential neuroprotective strategies may be developed for VD and related neurodegenerative diseases using the 2-VO rat model. Therefore, in the present study, CCH induced by 2-VO was used to investigate the neuroprotective effects of 7, 8-DHF on cognitive impairment.

Among behaviour tasks, the MWM test is widely used to measure spatial and learning memory whereas the NOR test is extensively used to evaluate recognition memory. In the current study, 2-VO rats showed longer escape latency along with a reduction in the number of entries and time spent in the target quadrant. Moreover, the discrimination index a measure of cognitive dysfunction was also significantly decreased in 2-VO rats. This data suggests that CCH secondary to 2-VO results in impairment in spatial and recognition memory. Interestingly, results from our study illustrated that administration of 7,8-DHF alleviates cognitive decline in 2-VO rats. Indeed, in earlier studies 7,8-DHF has been shown to reverse memory deficit in AD, schizophrenia, and Fragile X syndrome [14]. Moreover, 7,8-DHF is also known to counteract age-related decline in synaptic plasticity and spatial memory [15].

In addition, to behavioural changes, we also observed neurotransmitter alterations following CCH which are consistent with earlier experimental studies [32]. CCH caused a significant elevation in hippocampal glutamate levels whereas GABA levels were reduced. Interestingly, 2-VO rats treated with 7,8-DHF significantly reduced hippocampal glutamate levels and boosted GABA levels. Glutamate is an excitatory neurotransmitter that is responsible for synaptic transmission and long-term potentiation (LTP) process. However, excessive glutamate accumulation in the synaptic cleft leads to neuronal damage, a phenomenon known as excitotoxicity. It is well known that under ischemic conditions the activity of glial glutamate transporters ceases. Moreover, the pro-inflammatory cytokine TNF-α is also known to increase the expression of astrocytic glutaminase, which is known to convert glutamine to glutamate [33]. These events may lead to increased accumulation of glutamate in the extracellular space promoting neuronal excitotoxicity.

In the present study, we also observed a reduction in ACh levels in 2-VO rats. This could be attributed to the enhanced degradation of ACh into acetate and choline by AChE. Loss of cholinergic neurons along with reduced AChE activity has been observed in VD patients in the hippocampus, striatum cortex, and CSF. On this basis, numerous clinical studies have reported the benefits of AChE inhibitors, in improving cognitive function in mild to moderate VD [34]. Our results showed that AChE activity was elevated whereas ACh levels were reduced in the hippocampus of 2 VO rats. Treatment with 7,8-DHF effectively attenuated central cholinergic dysfunction. It has been reported earlier that 7,8-DHF treatment improved cognitive function by decreasing elevated hippocampal AChE activity in alcohol and HFD-fed animals and sporadic Alzheimer’s disease (SAD) model rats[13, 18]. These findings indicate the potential of 7,8-DHF as a cholinergic agent for VD treatment.

Oxidative stress and neuroinflammation are important mechanisms of neuronal injury and cognitive impairment induced by CCH. Reactive oxygen species (ROS) generated during CCH are known to oxidize intracellular molecules, such as membrane proteins, lipids, and DNA, and promote cellular apoptosis. Consistent with previous reports, the present findings indicated that MDA and PCO levels were increased in the hippocampus of CCH rats, indicative of oxidative damage to lipids and proteins [17, 35]. Moreover, reduced GSH levels and GPx, CAT, and SOD activities indicated compromised anti-oxidative machinery. In addition to oxidative stress, we also observed elevated levels of TNF-α, IL-1β, and NF-kβ in the hippocampus of VD rats. It has been found that following CCH the number of microglial cells is increased, and activated microglia release pro-inflammatory cytokines that mediate secondary brain damage [36]. Elevated TNF-α concentration can promote glutamate neurotoxicity, eventually leading to neuronal and oligodendrocyte cell death. Increased levels of IL-1β in the hippocampus may affect long-term potentiation, resulting in impaired learning and memory [37, 38]. Moreover, it also has been reported that in response to ROS, CCH induces activation of NF-kB, which is known to be involved in astrocyte inflammatory cascades, axonal loss, oligodendrocyte death, demyelination, and loss of white matter integrity [39].7,8-DHF treatment reversed hippocampal MDA and PCO levels and boosted anti-oxidative defenses. Furthermore, 7,8-DHF treatment also significantly reduced the levels of TNF-α and IL-1β which is most likely mediated by its ability to suppress hippocampal NF-κβ levels. Previous studies have reported that 7,8-DHF possesses potent antioxidant, anti-inflammatory and anti-apoptotic properties. The presence of two adjacent hydroxyl groups as electron donors has led to the notion that 7,8-DHF may be a direct free radical scavenger[40]. Furthermore, 7,8-DHF reduced ROS production and enhanced cellular GSH levels caused by glutamate in a hippocampal HT-22 cell line[41]. Similarly, 7,8-DHF increased SOD activity and demonstrated direct free radical scavenging against 6-OHDA-induced cytotoxicity [42].7,8-DHF has also shown to protect cortical neurons and RGC (retinal ganglion cells) and PC12 cells from oxidative stress and excitotoxic and induced apoptosis and cell death [12]. Regarding its anti-apoptotic actions in earlier studies, 7,8-DHF has been shown to increase Akt phosphorylation which is known to prevent the inhibition of anti-apoptotic Bcl-2 by inactivating pro-apoptotic factors [10]. Moreover, in a recent study Ahmed, Kwatra [43] reported that 7,8-DHF upregulated the PI3K-Akt pathway leading to Akt phosphorylation which inhibited apoptosis by phosphorylating Bad at serine-136.

The upregulation of BDNF expression may be another possible mechanism for the neuroprotective action of 7, 8 DHF. BDNF is a major neurotrophic factor that is involved in various neurophysiological processes such as neuronal differentiation, maturation and survival, and neurogenesis[44, 45]. BDNF has been detected in the cerebral cortex, hippocampus, cerebellum, and amygdala, in both rodents and humans, with the highest levels found in hippocampal neurons [6]. It is also known to exert a neuroprotective effect under adverse conditions, such as cerebral ischemia, hypoglycemia, glutamatergic stimulation, and neurotoxicity [45]. BDNF is also known to induce long-term potentiation (LTP) that is linked to synaptic plasticity and learning and memory abilities [7]. In the present study, CCH reduced the hippocampal p-AKT, p-CREB, and BDNF, and this effect was reduced in treatment with 7,8-DHF. It has been reported that CREB becomes active and up-regulates BDNF expression when protein kinases such as AKT phosphorylate it at the serine-133 residue [46]. CREB is also involved in the transcription of various genes that are essential for learning and memory. Moreover, previous studies have shown that the maintenance of long-term potentiation is impaired due to a diminished level of CREB in hippocampus slices [47]. In the current study, it is possible that treatment with 7,8-DHF enhanced BDNF synthesis and release through phosphorylation of CREB which lead to the reduction in 2-VO-induced cognitive decline. Indeed, in earlier studies, 7,8-DHF treatment is known to upregulate BDNF mRNA by enhancing neuronal CREB activation in experimental models of intracerebral haemorrhage, traumatic brain, and spinal cord injuries [10, 48].

In conclusion, our study demonstrated that 7,8-DHF mitigates CCH-induced cognitive impairments and exerted neuroprotective effects by the inhibition of oxidative stress, inflammatory responses, and apoptosis as well as the regulation of the cholinergic system. Moreover, the mechanism of 7,8-DHFon memory impairment may also be related to the activation of the hippocampal AKT/CREB/BDNF signalling pathway and the amelioration of neurochemical alterations. These results indicate that 7,8-DHF could be a promising treatment against aging-related diseases, such as VD.

Author contribution statement

K.C and N.D conceived and designed the present study. J.D and N.D carried out the experiments and analysed and interpreted the data. N.D wrote and edited the manuscript. All authors read and approved the manuscript.

Funding information

This experimental work did not receive any specific grant from any funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest the authors declare no conflict of interest.

Availability of data and materials All data generated and/ or analyzed during this study are included in this article

Luo X-Q, Li A, Yang X, Xiao X, Hu R, Wang T-W, Dou X-Y, Yang D-J, Dong Z (2018) Paeoniflorin exerts neuroprotective effects by modulating the M1/M2 subset polarization of microglia/macrophages in the hippocampal CA1 region of vascular dementia rats via cannabinoid receptor 2. Chin Med 13:1–17
Eyileten C, Kaplon-Cieslicka A, Mirowska-Guzel D, Malek L, Postula M (2017) Antidiabetic effect of brain-derived neurotrophic factor and its association with inflammation in type 2 diabetes mellitus. J Diabetes Res 2017: 1–14
Venkat P, Culmone L, Chopp M, Landschoot-Ward J, Wang F, Zacharek A, Chen J (2020) HUCBC Treatment Improves Cognitive Outcome in Rats With Vascular Dementia. Front Aging Neurosci 12:258
Zhang Z-Y, Liu Z, Deng H-H, Chen Q (2018) Effects of acupuncture on vascular dementia (VD) animal models: a systematic review and meta-analysis. BMC Complement Altern Med 18:1–10
Zhang Y, Wang LL, Wu Y, Wang N, Wang SM, Zhang B, Shi CG, Zhang SC (2016) Paeoniflorin attenuates hippocampal damage in a rat model of vascular dementia. Exp Ther Med 12:3729–3734
Miranda M, Morici JF, Zanoni MB, Bekinschtein P (2019) Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain. Front Cell Neurosci 13:363
Zhen Y-F, Liu X-Y, Zhou D-H, Du X, Yin G, Zhang Y, Fang H, Xu G, Soares JC, Zhang XY (2018) Cognition, serum BDNF levels, and BDNF Val66Met polymorphism in type 2 diabetes patients and healthy controls. Oncotarget 9:3653
Wang D-P, Yin H, Lin Q, Fang S-P, Shen J-H, Wu Y-F, Su S-H, Hai J (2019) Andrographolide enhances hippocampal BDNF signaling and suppresses neuronal apoptosis, astroglial activation, neuroinflammation, and spatial memory deficits in a rat model of chronic cerebral hypoperfusion. Naunyn Schmiedeb Arch Pharmacol 392:1277–1284
Wan Q, Ma X, Zhang Z-J, Sun T, Xia F, Zhao G, Wu Y-M (2017) Ginsenoside reduces cognitive impairment during chronic cerebral hypoperfusion through brain-derived neurotrophic factor regulated by epigenetic modulation. Mol Neurobiol 54:2889–2900
Wu C-H, Hung T-H, Chen C-C, Ke C-H, Lee C-Y, Wang P-Y, Chen S-F (2014) Post-injury treatment with 7, 8-dihydroxyflavone, a TrkB receptor agonist, protects against experimental traumatic brain injury via PI3K/Akt signaling. PLoS ONE 9:e113397
Agrawal R, Noble E, Tyagi E, Zhuang Y, Ying Z, Gomez-Pinilla F (2015) Flavonoid derivative 7, 8-DHF attenuates TBI pathology via TrkB activation. Biochim Biophys Acta Mol Basis Dis 1852:862–872
Liu C, Chan CB, Ye K (2016) 7, 8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders. Transl Neurodegen 5:1–9
Pandey SN, Mohit K, Dwivedi DK, Priyansha C, Mangala L, Ashok J (2020) 7, 8-Dihydroxyflavone alleviated the high-fat diet and alcohol-induced memory impairment: behavioral, biochemical and molecular evidence. Psychopharmacology 237:1827–1840
Tan Y, Nie S, Zhu W, Liu F, Guo H, Chu J, Cao XB, Jiang X, Zhang Y, Li Y (2016) 7, 8-dihydroxyflavone ameliorates cognitive impairment by inhibiting expression of tau pathology in ApoE-knockout mice. Front Aging Neurosci 8:287
Zeng Y, Lv F, Li L, Yu H, Dong M, Fu Q (2012) 7, 8-dihydroxyflavone rescues spatial memory and synaptic plasticity in cognitively impaired aged rats. J Neurochem 122:800–811
Castello NA, Nguyen MH, Tran JD, Cheng D, Green KN, LaFerla FM (2014) 7, 8-Dihydroxyflavone, a small molecule TrkB agonist, improves spatial memory and increases thin spine density in a mouse model of Alzheimer disease-like neuronal loss. PLoS ONE 9:e91453
Dhaliwal N, Dhaliwal J, Singh A, Chopra K (2021) Dimethyl fumarate attenuates 2-VO-induced vascular dementia via activating the Nrf2 signaling pathway in rats. Inflammopharmacology 29:537–547
Akhtar A, Dhaliwal J, Sah SP (2021) 7, 8-Dihydroxyflavone improves cognitive functions in ICV-STZ rat model of sporadic Alzheimer’s disease by reversing oxidative stress, mitochondrial dysfunction, and insulin resistance. Psychopharmacology:1–19
Jian W-x, Zhang Z, Zhan J-h, Chu S-f, Peng Y, Zhao M, Wang Q, Chen N-h (2020) Donepezil attenuates vascular dementia in rats through increasing BDNF induced by reducing HDAC6 nuclear translocation. Acta Pharmacol Sin 41:588–598
Sachdeva AK, Chopra K (2015) Lycopene abrogates Aβ (1–42)-mediated neuroinflammatory cascade in an experimental model of Alzheimer’s disease. J Nutr Biochem 26:736–744
Wills E (1965) Mechanisms of lipid peroxide formation in tissues role of metals and haematin proteins in the catalysis of the oxidation of unsaturated fatty acids. Biochim Biophys Acta Lipids Lipid Metab 98:238–251
Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz A-G, Ahn B-W, Shaltiel S, Stadtman ER (1990) [49] Determination of carbonyl content in oxidatively modified proteins. Methods in enzymology. Elsevier, pp 464–478
Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70–77
Kono Y (1978) Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys 186:189–195
Lawrence RA, Burk RF (1976) Glutathione peroxidase activity in selenium-deficient rat liver. Biochem Biophys Res Comm 71:952–958
Ellman GL, Courtney KD, Andres V Jr, Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95
Bernt E, Bergmeyer HU (1974) l-Glutamate UV-assay with gutamate dehydrogenase and NAD. Methods of enzymatic analysis. Elsevier, pp 1704–1715
Yadav M, Parle M, Jindal DK, Sharma N (2018) Potential effect of spermidine on GABA, dopamine, acetylcholinesterase, oxidative stress and proinflammatory cytokines to diminish ketamine-induced psychotic symptoms in rats. Biomed Pharmacother 98:207–213
Naik B, Nirwane A, Majumdar A (2017) Pterostilbene ameliorates intracerebroventricular streptozotocin induced memory decline in rats. Cogn Neurodyn 11:35–49
Liu D-d, Yuan X, Chu S-f, Chen C, Ren Q, Luo P, Lin M-y, Wang S-s, Zhu T-b, Zhang D-m (2019) CZ-7, a new derivative of Claulansine F, ameliorates 2VO-induced vascular dementia in rats through a Nrf2-mediated antioxidant responses. Acta Pharmacol Sin 40:425–440
Sohn E, Kim YJ, Lim H-S, Kim B-Y, Jeong S-J (2019) Hwangryunhaedok-Tang exerts neuropreventive effect on memory impairment by reducing cholinergic system dysfunction and inflammatory response in a vascular dementia rat model. Molecules 24:343
Bhuvanendran S, Bakar SNS, Kumari Y, Othman I, Shaikh MF, Hassan Z (2019) Embelin improves the spatial memory and hippocampal long-term potentiation in a rat model of chronic cerebral hypoperfusion. Sci Rep 9:1–11
Belov Kirdajova D, Kriska J, Tureckova J, Anderova M (2020) Ischemia-triggered glutamate excitotoxicity from the perspective of glial cells. Front Cell Neurosci 14:51
Wang J, Zhang H-Y, Tang X-c (2009) Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment. Acta Pharmacol Sin 30:879–888
Hu Y, Yang Y, Zhang M, Deng M, Zhang J-J (2017) Intermittent fasting pretreatment prevents cognitive impairment in a rat model of chronic cerebral hypoperfusion. J Nutr 147:1437–1445
Zhao Y, Zhang J, Zheng Y, Zhang Y, Zhang X, Wang H, Du Y, Guan J, Wang X, Fu J (2021) NAD + Improves Cognitive Function and Reduces Neuroinflammation By Ameliorating Mitochondrial Damage and Decreasing ROS Production in Chronic Cerebral Hypoperfusion Models Through Sirt1/PGC-1α Pathway. J Neuroinflamm 18:1–16
Chen N, Chen X, Xie J, Wu C, Qian J (2019) Dexmedetomidine protects aged rats from postoperative cognitive dysfunction by alleviating hippocampal inflammation. Mol Med Rep 20:2119–2126
Bourgognon J-M, Cavanagh J (2020) The role of cytokines in modulating learning and memory and brain plasticity. Brain Neurosci Adv 4:2398212820979802
Saggu R, Schumacher T, Gerich F, Rakers C, Tai K, Delekate A, Petzold GC (2016) Astroglial NF-kB contributes to white matter damage and cognitive impairment in a mouse model of vascular dementia. Acta Neuropathol Comm 4:1–10
Kang JS, Choi I-W, Han MH, Kim G-Y, Hong SH, Park C, Hwang HJ, Kim CM, Kim BW, Choi YH (2015) The cytoprotective effects of 7, 8-dihydroxyflavone against oxidative stress are mediated by the upregulation of Nrf2-dependent HO-1 expression through the activation of the PI3K/Akt and ERK pathways in C2C12 myoblasts. Int J Mol Med 36:501–510
Chen J, Chua K-W, Chua CC, Yu H, Pei A, Chua BH, Hamdy RC, Xu X, Liu C-F (2011) Antioxidant activity of 7, 8-dihydroxyflavone provides neuroprotection against glutamate-induced toxicity. Neurosci Lett 499:181–185
Han X, Zhu S, Wang B, Chen L, Li R, Yao W, Qu Z (2014) Antioxidant action of 7, 8-dihydroxyflavone protects PC12 cells against 6-hydroxydopamine-induced cytotoxicity. Neurochem Int 64:18–23
Ahmed S, Kwatra M, Gawali B, Panda SR, Naidu V (2021) Potential role of TrkB agonist in neuronal survival by promoting CREB/BDNF and PI3K/Akt signaling in vitro and in vivo model of 3-nitropropionic acid (3-NP)-induced neuronal death. Apoptosis 26:52–70
Kowiański P, Lietzau G, Czuba E, Waśkow M, Steliga A, Moryś J (2018) BDNF: a key factor with multipotent impact on brain signaling and synaptic plasticity. Cell Mol Neurobiol 38:579–593
Bathina S, Das UN (2015) Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci: AMS 11:1164
Yu X, Guan Q, Wang Y, Shen H, Zhai L, Lu X, Jin Y (2019) Anticonvulsant and anti-apoptosis effects of salvianolic acid B on pentylenetetrazole-kindled rats via AKT/CREB/BDNF signaling. Epilepsy Res 154:90–96
Kalivarathan J, Kalaivanan K, Chandrasekaran SP, Nanda D, Ramachandran V, Venkatraman AC (2020) Apigenin modulates hippocampal CREB-BDNF signaling in high fat, high fructose diet-fed rats. J Funct Foods 68:103898
Wu C-H, Chen C-C, Hung T-H, Chuang Y-C, Chao M, Shyue S-K, Chen S-F (2019) Activation of TrkB/Akt signaling by a TrkB receptor agonist improves long-term histological and functional outcomes in experimental intracerebral hemorrhage. J Biomed Sci 26:1–16

Table 1: Effect of 7, 8-DHF treatment on hippocampal oxidative stress markers and antioxidant indices in 2-VO rats

Groups	LPO (nmol/mg protein	PCO (nmol/mg protein)	GSH (nmol/mg protein)	SOD (U/mg protein)	Catalase (μM of H₂O₂/min/mg protein)	GPx (nmol/min/mg protein)
Sham	1.2±0.11	6.12±1.23	55.1±9.19	51.75±9.35	0.52±0.04	48.78±6.49
Sham+7,8-DHF(20)	1.31±0.20	8.44±1.99	58±9.25	54.30±7.22	0.61±0.13	33.39±5.69
2-VO	4.78±0.84^*	25.11±4.24^*	8.74±1.29^*	10.09±2.64^*	0.14±0.02^*	12.69±1.83^*
2-VO+7,8-DHF(5)	2.89±0.22^#	18.91±1.78	23.86±2.18	21.92±2.59	0.27±0.04	21.89±2.82
2-VO+7,8-DHF(10)	2.51±0.25^#	14.79±1.62^#	35.32±2.17^#	30.62±2.58^#	0.41±0.02^#	30.76±1.89^#
2-VO+7,8-DHF(20)	2.04±0.11^#	12.05±1.74^#	39.97±3.32	36.96±3.81	0.47±0.03^#	38.96±4.75^#,α
2-VO+DNPZ	3.09±0.28^#	17.98±1.34	27.67±2.14	22.27±3.23	0.24±0.02	19.93±1.42

Data values are expressed as mean ± SD. n=6 in each group.^*p < 0.05 as compared to sham group, ^#p < 0.05 as compared to 2-VO group, ^αp < 0.05 as compared DNPZ. 7,8-DHF:7,8-dihydroflavone, DNPZ: donepezil.

Table 2: Effect of 7, 8- DHF on hippocampal Glu, ACh, and GABA levels in 2-VO rats

Groups	Glutamate (µM/g of tissue)	Ach (µmol/mg prot)	GABA (nmol/mg prot)
Sham	17.19±3.62	30.24±3.24	123.83±10.37
Sham+7,8-DHF(20)	14±2.34	28.63±3.37	117.57±14.08
2-VO	53.87±6.81^*	6.72±1.01^*	88.68±11.5
2-VO+7,8-DHF(5)	39.27±7.17	11.65±2.19	93.03±10.96
2-VO+7,8-DHF(10)	32.31±5.86	18.26±1.17^#	101.33±14.5
2-VO+7,8-DHF(20)	23.78±4.46^#	20.98±1.56^#	109.87±9.13
2-VO+DNPZ	38.44±4.59	25.01±2.79^#	99.63±11.27

Data values are expressed as mean ± SEM. n=3 in each group.^*p < 0.05 as compared to sham group, ^#p < 0.05 as compared to 2-VO group. 7,8-DHF: 7,8-dihydroflavone, DNPZ: donepezil

No competing interests reported.

Download PDF

Journal Publication

published 01 Feb, 2024

Read the published version in Neurochemical Research →

Editorial decision: Major revision
02 Sep, 2023
Reviews received at journal
22 Aug, 2023
Reviewers agreed at journal
13 Aug, 2023
Reviewers invited by journal
12 Aug, 2023
Editor assigned by journal
08 Aug, 2023
Submission checks completed at journal
06 Aug, 2023
First submitted to journal
06 Aug, 2023

You are reading this latest preprint version

7, 8-dihydroxyflavone ameliorates cholinergic dysfunction, inflammation, oxidative stress, and apoptosis via activation of Akt/CREB/BDNF signaling pathway in a rat model of vascular dementia

Status:

Journal Publication

Version 1

Abstract

Background

Methods

Results

Conclusions

Figures

1. Introduction

2. Materials and Methods

2.1 Animals

2.2 Drugs and reagents

2.3 Surgical procedure and drug treatment

2.4 Behavioral assessments

2.4.1 Closed field activity

2.4.2 Morris water maze test

2.4.3 Novel object recognition (NOR) test

2.4.4 Tissue sampling

2.4.5 Estimation of lipid peroxidation

2.4.6 Estimation of protein carbonyls

2.4.7 Estimation of reduced glutathione levels (GSH)

2.4.8 Estimation of superoxide dismutase activity

2.4.9 Estimation of catalase activity

2.4.10 Estimation of glutathione peroxidase (GSH-Px) activity

2.4.11 Estimation of acetylcholinesterase (AChE) activity

2.4.12 Neurotransmitter analysis

2.5 Enzyme-Linked Immunosorbent Assay (ELISA)

2.5.1 TNF-α and IL-1β estimations

2.5.2 p-AKT and p-CREB estimations

2.5.3 BDNF Estimation

2.5.4 NF-kβ, Bcl-2, and Bax estimations

2.6 Statistical analysis

3. Results

3.1 Effect of 7, 8 DHF on locomotor activity in 2-VO rats

3.2 Effect of 7, 8 DHF on cognitive function in 2-VO rats

3.3 Effect of 7, 8 DHF on hippocampal cholinergic activity in 2-VO rats

3.4 Effect of 7, 8 DHF on hippocampal oxidative stress and anti-oxidant status

3.5 Effect of 7, 8-DHF on hippocampal TNF-α, IL-1β, and NF-kβ levels

3.6 Effect of 7, 8-DHF on hippocampal p-AKT, p-CREB, and BDNF levels in 2-VO rats

3.7 Effect of 7, 8-DHF on hippocampal Bcl-2, Bax and caspase-3 levels in 2-VO rats

3.8 Effect of 7, 8 DHF on hippocampal ACh, GABA, and Glu levels in 2-VO rats

4. Discussion

Conclusion

Declarations

References

Tables

Additional Declarations

Status:

Journal Publication

Version 1